The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 14, 2020
Filed:
Sep. 20, 2017
Applicant:
Resverlogix Corp., Calgary, CA;
Inventor:
Henrik C. Hansen, Calgary, CA;
Assignee:
Resverlogix Corp., Calgary, Alberta, CA;
Primary Examiner:
Int. Cl.
CPC ...
C07D 403/12 (2006.01); A61K 31/517 (2006.01); A61K 31/4375 (2006.01); A61K 31/472 (2006.01); A61K 31/496 (2006.01); A61K 31/519 (2006.01); A61K 31/5377 (2006.01); C07D 217/24 (2006.01); C07D 239/91 (2006.01); C07D 279/02 (2006.01); C07D 401/04 (2006.01); C07D 405/04 (2006.01); A61K 31/44 (2006.01); A61K 31/47 (2006.01); A61K 31/497 (2006.01); A61K 31/535 (2006.01); A61K 31/54 (2006.01); C07D 471/04 (2006.01); C07F 7/18 (2006.01); A61K 31/695 (2006.01); A61L 29/16 (2006.01); A61L 31/16 (2006.01);
U.S. Cl.
CPC ...
A61K 31/517 (2013.01); A61K 31/4375 (2013.01); A61K 31/44 (2013.01); A61K 31/47 (2013.01); A61K 31/472 (2013.01); A61K 31/496 (2013.01); A61K 31/497 (2013.01); A61K 31/519 (2013.01); A61K 31/535 (2013.01); A61K 31/5377 (2013.01); A61K 31/54 (2013.01); A61K 31/695 (2013.01); A61L 29/16 (2013.01); A61L 31/16 (2013.01); C07D 217/24 (2013.01); C07D 239/91 (2013.01); C07D 279/02 (2013.01); C07D 401/04 (2013.01); C07D 403/12 (2013.01); C07D 405/04 (2013.01); C07D 471/04 (2013.01); C07F 7/1804 (2013.01); A61L 2300/204 (2013.01); A61L 2300/606 (2013.01); A61L 2420/00 (2013.01);
Abstract
The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.